Rapid suppression of plasma HIV RNA and sustained increase in CD4 cell count following highly active antiretroviral therapy (HAART) regimens can be prognostic indicators of long-term virologic treatment success. Routine measurement of plasma HIV RNA levels (viral load or VL) at four and eight or 12 weeks is recommended after initiating treatment because favorable changes are predictive of durable success at six months and longer. Early favorable response of VL, as soon as six days after HAART initiation, can signify that the patient is initially adherent to treatment, which is necessary in the long term for a successful regimen. Early favorable response is also an indicator of adequate pharmacokinetic profile and potent antiviral activity of the drug regimen. It also can indicate that the predominant HIV strain infecting the patient is sensitive to the treatment regimen. These factors of adherence, drug levels, potency, and susceptibility favor a long-term durable response. Evaluation of early treatment responses may create the opportunity to promptly change the HAART regimen in the event of an anticipated long-term failure, delaying or preventing the evolution of drug resistance, and improving the effectiveness of treatment overall.
Introduction
In HIV/AIDS treatment, long-term suppression of plasma HIV RNA is associated with reductions in morbidity and mortality. 1, 2 Fluctuations in viral load and CD4 cell count with highly active antiretroviral therapy may indicate failure of the regimen. Loss of suppression of viremia may reflect poor adherence, inadequate drug levels, or virologic drug resistance Following initiation of HAART, patients with a rapid, large reduction in viral load have an increased likelihood of achieving long-term HIV suppression. [3] [4] [5] [6] [7] Viral load reductions as early as six days after treatment initiation correlate with longer-term response. 4 Effective antiretroviral therapy should induce a minimum 1.5 to 2.0 log 10 copies/mL reduction in viral load by four weeks. 8, 9 As components of a HAART regimen, lopinavir/ritonavir (LPV/r), tenofovir (TDF), efavirenz (EFV), and lamivudine (3TC) produce a very rapid decline in plasma HIV RNA levels, perhaps 80 percent of the theoretical calculated maximal activity of any regimen. 10 In addition to the importance of a rapid reduction in viral load, a significant relationship has been reported between the nadir plasma HIV RNA level (the lowest levels of HIV RNA observed on treatment) and durability of response. Nadir levels can also be predictive of the risk of disease progression. [11] [12] [13] Assessment of HIV dynamics during the first six days of HAART showed that rapid decay of HIV RNA was associated with durable response after 100 days on treatment ( Figure 1A ). 4 An analysis of seven antiretroviral therapy trials demonstrated that the risk of subsequent clinical disease progression was lower with greater viral load reductions after 24 weeks of treatment ( Figure 1B) ; this relationship was nearly linear (correlation: 0.98). 12 Failure to achieve a viral load of <50 copies/mL after treatment of 16 to 24 weeks should prompt concern for treatment failure, warranting a change in the therapeutic regimen, or addressing an adherence problem. However, patients with high baseline viral load (>100,000 copies/mL), or partial drug resistance may take longer to achieve maximal suppression than those with lower baseline loads, 14, 15 and immune reconstitution may also take longer. 16 Although findings stress the need for continuous viral load suppression, many patients on HAART experience intermittent low-level viral rebound or "blips" in viral load. The clinical implication of these blips remains controversial. One study 17 concluded that intermittent viremia during HAART was not associated with an increased risk of long-term viral rebound in patients who achieved viral suppression below the lower limit of quantitation (eg, HIV RNA levels of <50 copies/mL). In contrast, another study 18 reported that repeated episodic low-level viral rebound predicted future relapse, and indicated the persistence of a relatively larger latent reservoir of HIV. 19 Recent observation and research has elucidated reasons why HAART does not always result in rapid and/or sustained suppression of HIV replication and viremia. Failure of antiretroviral therapy is defined as one or more of the following: failure to attain VL suppression, a sustained increase in VL above the lower limit of quantitation after achieving suppression, an unsatisfactory change in CD4 cell count, and progression of clinical immune deficiency disease. 8 This article discusses the factors contributing to the success and failure of HAART that may be apparent early in treatment. These include adverse drug effects resulting in intolerance and nonadherence; variable or inadequate drug levels to suppress HIV replication to very low levels, or activation from latent or sequestered viral reservoirs; and drug resistance ( Table 1) .
Adverse effects and poor tolerability
Acute toxicities such as nausea, vomiting, headache, abdominal pain, and diarrhea are likely to limit initial drug tolerance and adherence in the short term. Where these symptoms are predictable and expected to be transient, patient education and support may be helpful in gaining long-term success.
Metabolic and other complications in patients with HIV infection have been attributed to antiretroviral therapy. [47] [48] [49] [50] [51] [52] They may result in poor tolerance to a new HAART regimen in the long term, although they may not prevent a rapid response in the short term. Metabolic disorders related to antiretroviral therapy include lipodystrophy, dyslipidemia, hepatotoxicity, insulin resistance and hyperglycemia, lactic acidemia, and bone disease. These can lead to drug discontinuation or the need to alter the antiretroviral therapeutic regimen. 2, 47, 51, 53 Mitochondrial toxicity of nucleoside reverse transcriptase inhibitors (NRTIs) has been implicated as a cause of HAART-related complications, including lipodystrophy and lactic acidemia. 54 A major concern is the possibility that HAART-associated Adapted with written permission from Marschner, et al, 12 The University of Chicago Press. metabolic disturbances may promote the development of cardiovascular disease. 48, [55] [56] [57] [58] Poor compliance to the new HAART regimen Many patients with HIV infection do not fully adhere to their HAART regimens, [59] [60] [61] and poor adherence early in the course of therapy leads to impaired response to HAART. [61] [62] [63] A study measured adherence among HIVinfected protease inhibitor (PI)-treated patients with a microelectronic monitoring system (MEMS) TrackCap System; Aprex; Union City, CA) for a median of six months (range: three to 15 months). It showed that non-adherence to antiretroviral therapy was highly significantly, and strongly associated with virologic failure 61 which was defined as HIV RNA level of >400 copies/mL at the last study visit ( Figure 3 ).
High pill burden is an important barrier to compliance. The impact of high pill burden was assessed in a metaanalysis of 23 clinical trials conducted with 3,257 HIVinfected, antiretroviral-naive patients. 64 The patients were treated with triple-combination therapy, consisting of two NRTIs plus a PI, a non-nucleoside reverse transcriptase inhibitor (NNRTI), or a third NRTI. This analysis revealed a highly significant relationship between higher pill burden and a lower percentage of patients with plasma HIV RNA levels of ≤50 copies/mL at 48 weeks of treatment. Lower pill burden combined with rational once-daily dosing should significantly improve adherence to HAART, and treatment outcome.
Pharmacokinetics
A significant relationship has been demonstrated between higher plasma antiretroviral drug concentrations and lower plasma viral loads, particularly with the protease inhibitors ( Figure 2 ). 20, 21 Drug concentrations that rapidly and durably suppress HIV replication can be impeded by physiologic factors and inherent characteristics of the drug that limit its bioavailability. Determining the level of exposure to individual antiretroviral drugs can show the relationship between pharmacokinetics and short-term virological response.
Physiologic factors: Cellular drug transporters (Pglycoprotein or P-gp) and cytochrome P450 isoenzyme activity (CYP3A4, CYP2C9, CYP2C19, and CYP2D6) are two physiologic factors that may affect HAART efficacy. Cellular drug transporters facilitate both uptake and efflux with effects on drug delivery to their site of action, so that transporter activity can have an impact on antiretroviral drug absorption, intracellular distribution, and action. Several studies suggest that P-gp, a cellular efflux pump encoded by the multi-drug resistant (MDR)-1 gene, influence the bioavailability of some drugs, including PIs. [23] [24] [25] P-gp in the intestine can impede drug absorption by pumping the drug back into the gastrointestinal (GI) tract, whereas P-gp in the liver can pump the drug into the bile for elimination. 26 P-gp present at the blood-brain barrier can limit the uptake of drugs into the cerebrospinal fluid. Induction of P-gp expression may explain the reduced drug levels that persist even after multiple doses of PIs. 26 Physiologic differences among individuals in the activity of the cytochrome P450 3A4 isoenzyme, and differences in CYP2C9, CYP2C19, and CYP2D6 isoenzymes, may contribute to metabolic variability of both PIs and nonnucleoside reverse transcriptase inhibitors. Differences in CYP3A activity have been linked to variations in CYP3A gene expression, race, gender, diet, and liver disease. [27] [28] [29] Inherent drug characteristics: For NRTIs, which are intracellularly phosphorylated to the active triphosphate, there is poor correlation between drug plasma levels and antiretroviral efficacy. Plasma levels of PIs and NNRTIs need to be above some arbitrary effective concentration (EC) of the virus for the entire dosing interval to achieve effective suppression of HIV replication. 21 For some existing antiretroviral agents, tolerability and bioavailability have been improved by reformulation. With didanosine (ddI) treatment, pharmacokinetic evaluation showed no increase in total systemic drug exposure (adjusted for dose) between once-daily and twice-daily drug administration. 22 For example, the efficacy and level of exposure from the enteric-coated formulation of didanosine was retained without doselimiting gastrointestinal side effects. Reformulation of saquinavir (SQV) from hard-to soft-gel capsules increased bioavailability and improved anti-HIV activity. 30 A pro-drug HIV reservoirs: Patients on HAART with an undetectable plasma viral load may have persistent HIV reservoirs that prevent eradication of the infection. [39] [40] [41] [42] Long-lived, latently infected resting memory CD4 cells have been identified in the plasma and lymphatic tissues in patients with undetectable plasma HIV RNA levels during long-term HAART. 40, 44 Secondly, pharmacologic sanctuaries of viral replication may facilitate emergence of drug resistance. 43 Potential sites of active viral reservoirs include the central nervous system and the genitourinary tract. 45, 46 HIV sequestered in these sanctuary sites appears to retain resistance mutations. For these reasons, subsequent use of previously employed and related antiretroviral agents may be ineffective. 43 Patients may not achieve rapid suppression of HIV RNA, or may rapidly rebound from incomplete suppression. Thus, maintaining a log of past treatments, outcomes, and drug resistance is important for decisions about subsequent therapy.
Drug resistance
Failure to maintain adequate blood drug levels to suppress HIV replication can permit emergence of drug resistance. Natural selection from continued drug pressure will lead to predominance of drug-resistant virus in an individual. Some patients may experience viral rebound that is not 
-

characterized by resistant variants. 31, 32 Because of the error-prone nature of HIV reverse transcriptase, viral rebound can then facilitate emergence of drug-resistant HIV variants over short periods of time. 33 Emergence of variants can confer cross-resistance to other antiretroviral agents within the same class, causing the failure of subsequent antiretroviral regimens. 34 In antiretroviral-naive patients, failure of HAART early in treatment may reflect the acquisition of a drug-resistant HIV variant during primary infection. Transmission of drug-resistant HIV occurs with significant prevalence (range: 1 percent to 11 percent) in patients with primary HIV infection or in those who have recently undergone seroconversion. [35] [36] [37] [38] Identification of HIV variants with resistance to one or more drugs increased in recently infected patients from 3.4 percent between 1995 and 1998, to 12.4 percent between 1999 and 2000 (p=0.002). 38 Currently available tests to determine drug resistance can be used to guide choices of antiretroviral regimens, particularly in cases of recent HIV infection, or treatment failure.
Facilitating early response to HAART
Optimal antiretroviral therapy should induce a rapid, durable reduction of HIV RNA and a sustained increase in CD4 cell count. The regimen should be well tolerated and ideally involve simple dosing requirements with a low pill burden. 9 The US Department of Health and Human Services guidelines for the treatment of HIV infection strongly recommend that first-line antiretroviral therapy include efavirenz, indinavir (IDV), nelfinavir (NFV), lopinavir/ ritonavir, indinavir/ritonavir, or saquinavir/ritonavir, in conjunction with two NRTIs. 2 "Strongly recommended" NRTI components include stavudine (d4T)/lamivudine, stavudine/didanosine, zidovudine (ZDV)/lamivudine, didanosine/zidovudine, and didanosine/lamivudine. Strategies to improve the efficacy of HAART regimens include new antiretroviral agents, the use of therapeutic drug monitoring, and the use of low-dose ritonavir for pharmacokinetic enhancement or "boosting" of the primary PI ( [66] [67] [68] These patients had a baseline mean HIV RNA level of 3.7 log 10 copies/mL and extensive prior antiretroviral experience. Nearly all of the patients (97 percent) exhibited NRTI resistance mutations at baseline. In a phenotypic analysis of tenofovir susceptibility, baseline HIV resistance to tenofovir DF correlated significantly with the magnitude of the response to treatment (p=0.007). 66 Phase III clinical trials 69, 70 supported the phase II findings. Approximately 81 percent of antiretroviral-naive patients receiving lamivudine and efavirenz in combination with once-daily tenofovir DF, or stavudine dosed twice daily achieved a viral load less than 50 copies/ml after 48 weeks of treatment. Inclusion of tenofovir in an initial or subsequent HAART regimen could facilitate rapid HIV suppression in patients.
T-20 is a synthetic peptide that interferes with a key region of the HIV envelope glyco-protein. It blocks HIVcell fusion and HIV entry into cells at concentrations less than 2 ng/mL in vitro. It also inhibits fusion of cells expressing the HIV envelope protein with CD4 cells. These are two novel mechanisms that can prevent cellular HIV infection. In both short-and long-term clinical studies, T-20 has been found to be safe and effective in significantly reducing plasma HIV RNA. T-20 is a promising new antiretroviral agent with mechanisms of action different from those of current antiretroviral drugs. 71, 72 Emtricitabine (a fluorinated cytosine analogue), an NRTI, exhibits activity against HIV that is four to ten times greater than lamivudine. 73 This agent can be dosed once daily. In a short-term clinical study (12 days) , emtricitabine monotherapy at 200 mg once daily resulted in significantly greater reductions in viral load than lamivudine monotherapy at 150 mg twice daily (p=.047). 74 However, in longer-term studies that lasted 24 or 48 weeks, the antiviral activity and tolerability of emtricitabine and lamivudine were similar. 75 Emtricitabine, studied in a once-daily HAART regimen in 40 previously untreated HIV-infected patients with a baseline median plasma HIV RNA level of 4.77 log 10 copies/mL, decreased HIV RNA by a median of 3.5 log 10 copies/mL at 24 weeks. Of these patients, 98 percent achieved plasma HIV RNA levels of less than 400 copies/mL, and 93 percent achieved levels of less than 50 copies/mL. 76, 77 In fact, the reduction in viral load to less than 400 copies/mL was maintained in 90 percent of patients for up to 64 weeks. 77 Adverse events included mild-tomoderate central nervous system symptoms (73 percent of patients), diarrhea (37 percent), rashes (10 percent), and laboratory abnormalities, but the regimen was generally well tolerated.
Tipranavir is a non-peptidic PI. 78 Because of its distinct chemical structure, investigators postulated that HIV, resistant to current PIs, would remain sensitive to tipranavir. This has been evaluated in pre-clinical studies. [79] [80] [81] The poor bioavailability and rapid metabolism of tipranavir after administration will require the combined use of ritonavir to achieve adequate plasma drug concentrations. 82 Tipranavir has been evaluated in both treatment-naive and PI-failure patients. A phase II clinical study in antiretroviral-naive patients (N = 31) involved treatment for two weeks with one of three treatment regimens: monotherapy with tipranavir 1,200 mg; combination therapy with tipranavir 300 mg/ritonavir 200 mg; or combination therapy with tipranavir 1,200 mg/ritonavir 200 mg. Respective reductions in viral load in these treatment groups were -0.8, -1.4, and -1.6 log 10 copies/mL from a median baseline of 5.02 log 10 copies/mL. 82 The most common side effects were diarrhea (52 percent of patients), nausea (23 percent), and vomiting (13 percent) . A phase II clinical study of patients who had failed their first PIcontaining regimen received randomized treatment with tipranavir 500 mg/ritonavir 100 mg, or tipranavir 1,250 mg/ritonavir 100 mg twice daily, plus two NRTIs. These groups demonstrated similar viral load reductions of 1.3 and 1.4 log 10 copies/mL respectively, by week 16.83 Studies have also been conducted in patients who failed two or more PI-containing regimens. 84 These patients received tipranavir 500 mg/ritonavir 100 mg or tipranavir 1,000 mg/ritonavir 200 mg twice daily, plus efavirenz and an NRTI. At 24 weeks, viral load reductions were similar between the treatment groups, -2.69 and -2.59 log 10 copies/mL respectively. 85 Based on additional dose-finding studies, a dose of 500 mg of tipranavir combined with 200 mg of ritonavir both dosed twice daily has been determined to balance tolerability with potency and is being studied in phase 3 trials.
Atazanavir, a potent once-daily PI in phase III clinical development, has a low pill burden of two capsules per day. This drug has a median in vitro effective concentration (EC 50 ) of 2 to 5 nM against a variety of HIV isolates in vitro. [86] [87] [88] When estimated drug levels are adjusted for protein binding, the calculated inhibitory quotient (IQ), defined as the ratio of expected C min to EC 50 of wild-type virus, is 10.2 to 25.5 for atazanavir. Claims of superiority of one PI over another drug based on the IQ are complicated by unstandardized in vitro methods, variable in vivo estimates and measures, and variable calculations. 89 However, studies do show correlation between IQ and clinical outcome, 90 or correlation between the "virtual IQ" (which includes the level of resistance of the patient HIV isolate to the drug evaluated) and clinical outcome. 91 In naive subjects, atazanavir monotherapy induces a rapid decline in viral load of approximately 1.5 log 10 copies/mL after two weeks of treatment. 92 Clinical trials show that atazanavir rapidly and durably suppresses HIV RNA, and durably increases CD4 cell count in both antiretroviral-naive and antiretroviral-experienced subjects. 93, 94 Reversible, asymptomatic elevations in unconjugated bilirubin are the most common laboratory abnormality associated with atazanavir treatment, although no hepatotoxicity has been observed. Atazanavir, unlike the currently approved PIs, is not associated with clinically relevant elevations in lipid levels in either antiretroviral-naive or antiretroviralexperienced subjects. 92, 95 Lipodystrophy appears more frequently in patients with dyslipidemia, [96] [97] [98] and the fear of developing lipodystrophy may reduce patients' willingness to remain on a current PI-containing HAART regimen. 99, 100 Therapeutic drug monitoring during early HAART: The objectives of therapeutic drug monitoring are to improve effectiveness of treatment by individualizing drug dosage guided by measuring individual drug levels. This is most useful for drugs with a narrow "therapeutic window"-the space between maximum tolerated, and minimum effective drug levels. One may identify sub-optimal plasma drug levels indicating a dose or drug change to improve treatment efficacy, or high drug levels to reduce dosage and to reduce toxicity without loss of efficacy. Both the technology and value of therapeutic drug monitoring in HIV have been described. 101, 102 Favorable drug concentrations alone, however, cannot consistently predict drug effectiveness because they do not account for drug resistance or other factors associated with treatment failure, such as inadequate adherence. The PharmAdapt study was conducted in patients failing a PI-drug regimen. It showed no difference in long-term virologic outcome in patients with or without PI drug monitoring. 103 Effective therapeutic drug monitoring in a broad patient base must reflect the relationship between drug levels and viral susceptibility. 104 Prospective clinical trials evaluating therapeutic drug monitoring as a tool for treatment modification have not incorporated virus susceptibility data into their protocols. [105] [106] [107] The optimal tests, schedules, and interpretations of antiretroviral drug concentrations have not been determined. As drugs with wider therapeutic windows are developed, therapeutic drug monitoring will become less of an issue.
Pharmacokinetic enhancement with ritonavir: Addition of ritonavir to a PI-containing regimen can improve short-term response, but it can also compromise long-term effectiveness with reduced tolerability and potentially altered long-term toxicities. The rationale for adding ritonavir is based on its inhibitory effect on the CYP450 3A4 enzyme system which extensively metabolizes the PIs and the NNRTIs. 27, 108 Ritonavir increases the absorption of primary PIs by inhibiting CYP450 3A4 in the intestine, and reduces drug elimination by inhibiting it in the liver. In most cases, these effects generally reduce the required number of daily doses of the primary PI, which may improve patient adherence. Combinations that have been studied include ritonavir plus saquinavir, 30, 109 ritonavir plus indinavir, [110] [111] [112] ritonavir plus amprenavir, [113] [114] [115] and ritonavir plus nelfinavir. 116 The optimal dosages for most of these combinations have not yet been established. 111, 117 With the combination of ritonavir and indinavir there appears to be an increase in crystalluria and nephrolithiasis at higher doses of ritonavir, as compared with indinavir alone, 118 or low doses of both ritonavir and indinavir. Ritonavir, in a dose-dependent manner, also causes dyslipidemia, increasing the concern for possible long-term cardiovascular complications.
Two ritonavir-enhanced regimens have recently received approval from the FDA. One is a co-formulation of lopinavir (formerly known as ABT-378), an analogue of ritonavir, with ritonavir into a single capsule. 119 A phase III trial compared ritonavir/lopinavir with nelfinavir given to patients who were treatment-naive, and found a significantly greater proportion achieved viral loads less than 400 and less than 50 copies/mL with lopinavir/ritonavir treatment than with nelfinavir (p<0.001). 120 For salvage therapy subjects who were NNRTI-naive, but highly PI-experienced, the combination of efavirenz and lopinavir/ritonavir led to durable viral suppression in the majority. 121, 122 This study also showed significantly fewer resistance mutations emerging in the subjects on lopinavir.
The other approved ritonavir-enhanced regimen is amprenavir/ ritonavir, 123 which is dosed either twice daily (amprenavir 600 mg/ritonavir 100 mg), or once daily (amprenavir 1,200 mg/ritonavir 200 mg). Notably, each amprenavir/ritonavir dosing schedule requires 10 capsules per day.
Conclusion
Evidence suggests that long-term effective antiretroviral therapy for HIV infection follows rapid reduction of viral loads to below a detectable or quantifiable level early in the course of treatment. The likelihood of long-term success can be evaluated as early as six days after initiating HAART. Although such early effects may occur with currently available regimens, several factors reduce the likelihood of achieving long-term therapeutic effectiveness. These include poor adherence to a complicated regimen early in treatment, inadequate drug pharmacokinetics, and the presence of drug-resistant HIV infection.
Innovative approaches to HAART have been designed to overcome these limitations. Novel antiretroviral agents, including tenofovir DF, emtricitabine, enfuvirtide, tipranavir, and atazanavir, may improve HAART regimens to better achieve an early response. Therapeutic drug monitoring determines plasma drug concentrations of PIs to individualize and ensure therapeutic dosing earlier, and to maintain sufficient drug exposure. Boosting PI pharmacokinetics with ritonavir simplifies regimens and improves response. However, increased drug levels due to ritonavir may lead to more undesirable long-term metabolic complications, including dyslipidemia. When a patient has a sub-optimal early response to therapy because of drug intolerance, non-adherence, inadequate drug levels, or drug resistance, a clinical decision may be made to change treatment to favor long-term effectiveness. ■
